Navigation Links
Portola Pharmaceuticals Announces Positive Phase II Results for,PRT054021 for Prevention of Venous Thromboembolism Following Total,Knee Replacement Surgery

Data to be Presented at the XXI Congress of the International Society on Thrombosis and Haemostasis

SOUTH SAN FRANCISCO, Calif., April 04, 2007 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced that it has received positive results from EXPERT, a Phase II study of its oral Factor Xa inhibitor, PRT054021, for the prevention of venous thromboembolism (VTE) following total knee replacement (TKR) surgery. Based on these results, Portola will advance PRT054021 into further clinical testing.

"Successful completion of EXPERT is a significant achievement and is the result of many years of work by the Portola team in the field of anticoagulants," said Charles Homcy, M.D., CEO of Portola. "We are pleased that the results of this study are consistent with our predicted therapeutic dose range for PRT054021."

EXPERT (Evaluation of the Factor Xa Inhibitor, PRT054021, against Enoxaparin in a Randomized Trial for the Prevention of Venous Thromboembolic Events after Unilateral Total Knee Replacement) enrolled over 200 patients at 20 medical centers in the United States and Canada in a randomized, active comparator, parallel-group trial. Patients were randomized to receive one of two oral doses of PRT054021, or Lovenox(R) (enoxaparin) given as a subcutaneous injection. The treatment period was for ten to fourteen days after surgery, at which time a venogram was obtained to determine the presence of VTE.

The EXPERT steering committee, which includes a group of leading physicians and orthopedic surgeons with significant experience in conducting clinical trials involving novel anticoagulants, determined that EXPERT met its objectives: PRT054021 appeared effective and safe at the two doses studied, and the results support advancing the compound into further clinical trials. Data from EXPERT will be presented at the XXI Congress of the International Society on Thrombosis and Haemostasis in Geneva, Swi
'"/>




Page: 1 2 3

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
3. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:12/19/2014)... 18, 2014 Research and Markets ... the "Micro Market Monitor: North American Dermatology ... http://photos.prnewswire.com/prnh/20130307/600769 ... steadily, which has resulted in fueling the overall ... main purpose of these dermatology devices is to ...
(Date:12/19/2014)... REDWOOD CITY, Calif., Dec. 18, 2014 ... on the development of medical diagnostics based on ... of gas flow, today announced financial results for ... 30, 2014. "Following the completion of ... well positioned to maximize the recently initiated CoSense® ...
(Date:12/19/2014)... Dec. 18, 2014 Since last month,s FBI ... now known as the leading online black market for ... growth in its offering of drugs and other illegal ... the takedowns did succeed in lowering the numbers of ... of the markets in August. But some new sites ...
Breaking Medicine Technology:Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3
...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announced ... a Generation 2.5 antisense drug designed to treat cancer.  ... activator of transcription 3 (STAT3). Because STAT3 is over ... potential to be broadly useful for both solid and ...
... 2012 The Board of Conformetrix Ltd, ... appointed Dr Sam Williams as Chief Executive Officer, it ... and business development expertise, was previously a Non-Executive Director ... Conformetrix,s founder scientists, Dr Andrew Almond, who becomes Chief ...
Cached Medicine Technology:Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 2Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 3Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 4Conformetrix Appoints Dr Sam Williams as Chief Executive Officer 2
(Date:12/22/2014)... December 22, 2014 Only weeks following ... and mid-western cities to have a battery manufacturer create ... ( http://www.talklocal.com ) is launching in Henderson ... , “A strong manufacturing sector is going to ... Gurpreet Singh explained, “and TalkLocal works with small businesses ...
(Date:12/22/2014)... December 22, 2014 Xarelto Lawsuit ... panel of judges has granted a request to centralize ... U.S. District Court, Eastern District of Louisiana. The U.S. ... on December 12 to transfer over 50 Xarelto cases–21 ... to the Louisiana court for consolidation under U.S. District ...
(Date:12/22/2014)... NAPW honors Michelle M. ... Year. Ms. Foley is recognized with this prestigious distinction ... organization of professional women in the country, spanning virtually ... Women is a powerfully vibrant networking community with over ... a nurse, I felt like I made a difference ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Parker & ... absolute best in Arizona home contracting services reports a ... to its quality services in 2014. As a company ... the early 1970s, Parker and Sons is a business ... The company works side-by-side with other top quality companies ...
(Date:12/21/2014)... Khanna Vision Institute is pleased to announce ... Helicopters holiday event for underprivileged kids. The highlight was ... by an aspen helicopter pilot. In the cover of ... was visible.(please see accompanying video). Helicopter pilots require great ... many pilots with Pi in eye vision correction. ...
Breaking Medicine News(10 mins):Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:National Association of Professional Women Announces Michelle M. Foley, Vice President of Operations of OTTR Chronic Care Solutions, a 2014 Professional Woman of the Year 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 3
... French . The medicinal use of cannabis has ... large for many years as an alternative to standard pharmaceutical ... may have unwanted side effects. A new study by McGill ... that cannabis may offer relief to patients suffering from chronic ...
... cannabis reduces pain, improves mood and helps sleep, ... Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj091414.pdf ... pain due to damage or dysfunction of the ... include opioids, anticonvulsants, antidepressants and local anesthetics, but ...
... Amanda Gardner HealthDay Reporter , FRIDAY, Aug. 27 ... real and pervasive condition, new research suggests there is a ... either to get drugs or gain special privileges in school. ... to do a good job of faking on a number ...
... . , Montreal, August 27, 2010 While some ... scientists at the University of Toronto and the University of ... in some adolescents. Published in the journal Addictive Behaviors ... in Teens (NDIT) study based at the University of Montreal ...
... HealthDay Reporter , THURSDAY, Aug. 26 (HealthDay News) ... salmonella bacteria in feed given to chickens at the two ... finding, at Iowa-based Wright County Egg and Hillandale Farms, ... of the salmonella outbreak, government experts said at a press ...
... Traumatic brain injury, currently considered a singular event by ... instead the beginning of an ongoing process that impacts ... diseases and disorders that can reduce life expectancy, according ... at Galveston. As such, traumatic brain injury should ...
Cached Medicine News:Health News:Research demonstrates benefits of medical cannabis as a treatment for chronic pain 2Health News:Smoked cannabis reduces chronic pain 2Health News:Some Fake ADHD to Get Meds, Special Treatment 2Health News:Some Fake ADHD to Get Meds, Special Treatment 3Health News:Smoking increases depressive symptoms in teens 2Health News:Chicken Feed May Be Source of Salmonella in Egg Recall: FDA 2Health News:Chicken Feed May Be Source of Salmonella in Egg Recall: FDA 3Health News:Researchers urge reclassification of traumatic brain injury as chronic disease 2Health News:Researchers urge reclassification of traumatic brain injury as chronic disease 3Health News:Researchers urge reclassification of traumatic brain injury as chronic disease 4
... Plus® 5.5 is excellent ... the optic nerve head ... with your binocular indirect ... neovascular membranes, macular edema, ...
The iQ200 Automated Urinalysis System (iQ System) is a user-friendly, bench top, fully automated system that performs complete urinalyses on unspun specimens; simply load, press START and walk away....
A flexible hematology platform:, 32 parameters, Automatic result validation, Cytology atlas included, CBC and 5+3 DIFF...
The PDM utilizes the latest technology for measuring interpupillary distance and left/right pupil-to-nose distance. Lightweight and easy-to-use, the PDM provides accurate and repeatable PD measuremen...
Medicine Products: